Update on malignant pleural mesothelioma.
暂无分享,去创建一个
[1] H. Kindler,et al. Malignant pleural mesothelioma: an update on biomarkers and treatment. , 2009, Chest.
[2] K. Rosenzweig,et al. Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] V. Rusch. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. , 1995, Chest.
[4] V. Rusch,et al. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. , 1996, Lung cancer.
[5] A. Gown,et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. , 2009, Archives of pathology & laboratory medicine.
[6] I. Goldman,et al. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. , 2002, Cancer research.
[7] W. Richards,et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Skates,et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma , 2007, Thorax.
[9] Eun‐Kee Park,et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. , 2008, American journal of respiratory and critical care medicine.
[10] G. Giaccone,et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Stupp,et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] M. Tiseo,et al. A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM). , 2010 .
[13] V. Torri,et al. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials , 2008, British Journal of Cancer.
[14] P. Hall,et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Gordon,et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. , 2009, Journal of the National Cancer Institute.
[16] C. Soskolne,et al. The Case for a Global Ban on Asbestos , 2010, Environmental health perspectives.
[17] Mitchell Ho,et al. Mesothelin targeted cancer immunotherapy. , 2008, European journal of cancer.
[18] F Rey,et al. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis , 1993, Cancer.
[19] R. Vernhout,et al. Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] J. Herndon,et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. , 1998, Chest.
[21] K. Rosenzweig,et al. Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER]) Population , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] M J Price,et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050 , 2005, British Journal of Cancer.
[23] R. Stahel,et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] K. Rosenzweig,et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. , 2005, International journal of radiation oncology, biology, physics.
[25] F. Galateau-Sallé,et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.
[26] G. Giaccone,et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] K. Bang,et al. Malignant mesothelioma mortality--United States, 1999-2005. , 2009, MMWR. Morbidity and mortality weekly report.
[28] W. Travis,et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer , 2010, Cancer Immunology, Immunotherapy.
[29] K. Nackaerts,et al. Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[30] J. V. van Meerbeeck,et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. , 2009, European journal of cancer.
[31] F. Cappuzzo,et al. Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma , 2008, Cancer.
[32] H. Kindler. Systemic Treatments for Mesothelioma: Standard and Novel , 2008, Current treatment options in oncology.
[33] A. Nicholson,et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial , 2008, The Lancet.
[34] Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province , 2005 .
[35] V. Seshan,et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. , 2008, The Journal of thoracic and cardiovascular surgery.
[36] S. Skates,et al. Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[37] G. Ceresoli,et al. Second-line treatment for malignant pleural mesothelioma. , 2010, Cancer treatment reviews.
[38] M. Krzakowski,et al. Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] S. Skates,et al. Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[40] N. O'Rourke,et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[41] A. Wozniak,et al. SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] E. Butchart,et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. , 1976, Thorax.
[43] E. Lau,et al. US mesothelioma patterns 1973–2002: indicators of change and insights into background rates , 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[44] Zhandong Liu,et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. , 2005, The New England journal of medicine.
[45] G. Scagliotti,et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] L. Schwartz,et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. , 2006, Clinical lung cancer.
[47] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] M. Millward,et al. Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). , 2010 .
[49] F. Rea,et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. , 2007, Lung cancer.
[50] C. Obasaju,et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] M. Tsao,et al. Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] P. V. Van Schil,et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial , 2010, European Respiratory Journal.
[53] J. Peto,et al. The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[54] G. Giaccone,et al. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). , 2003, European journal of cancer.
[55] V. Preedy,et al. European Organization for Research and Treatment of Cancer , 2010 .
[56] H. Kindler,et al. Malignant pleural mesothelioma , 2000, Current treatment options in oncology.
[57] J. Shamash,et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] P. Jänne,et al. A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[59] G. Scagliotti,et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] J. Shamash,et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] J. Testa,et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey , 2001, The Lancet.
[62] Bertram Price,et al. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. , 2004, American journal of epidemiology.
[63] Laurence Court,et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. , 2006, International journal of radiation oncology, biology, physics.
[64] R. Ramlau,et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] B. Christensen,et al. SV40 associated miRNAs are not detectable in mesotheliomas , 2010, British Journal of Cancer.
[66] A. Musk,et al. Mesothelin-family proteins and diagnosis of mesothelioma , 2003, The Lancet.
[67] K. Rosenzweig,et al. Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy and Photon-Electron Radiotherapy , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[68] Craig A. Poland,et al. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma , 2010, Particle and Fibre Toxicology.
[69] H. Anderson,et al. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. , 2009, Lung cancer.
[70] F. Rey,et al. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. , 1995, Chest.
[71] Helen X. Chen,et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) , 2007 .
[72] T. Powles,et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. , 2009, Lung cancer.
[73] A. Ceribelli,et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] M. Mencoboni,et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.